These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9448552)

  • 1. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
    Schwartz HJ; Petty T; Dubé LM; Swanson LJ; Lancaster JF
    Arch Intern Med; 1998 Jan; 158(2):141-8. PubMed ID: 9448552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E; Cohn J; Dubé L; Drazen JM
    JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
    DuBuske LM; Grossman J; Dubé LM; Swanson LJ; Lancaster JF
    Am J Manag Care; 1997 Apr; 3(4):633-40. PubMed ID: 10169531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
    Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
    Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and clinical efficacy of zileuton in patients with chronic asthma.
    Lazarus SC; Lee T; Kemp JP; Wenzel S; Dubé LM; Ochs RF; Carpentier PJ; Lancaster JF
    Am J Manag Care; 1998 Jun; 4(6):841-8. PubMed ID: 10181070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
    Nelson H; Kemp J; Berger W; Corren J; Casale T; Dube L; Walton-Bowen K; LaVallee N; Stepanians M
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):178-84. PubMed ID: 17718106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of zileuton on theophylline pharmacokinetics.
    Granneman GR; Braeckman RA; Locke CS; Cavanaugh JH; Dubé LM; Awni WM
    Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
    Wenzel SE; Kamada AK
    Ann Pharmacother; 1996; 30(7-8):858-64. PubMed ID: 8826571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.
    Wenzel S; Busse W; Calhoun W; Panettieri R; Peters-Golden M; Dube L; Walton-Bowen K; Russell H; Harris J
    J Asthma; 2007 May; 44(4):305-10. PubMed ID: 17530530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
    O'Connor BJ; Löfdahl CG; Balter M; Szczeklik A; Boulet LP; Cairns CB
    Respir Med; 2007 Jun; 101(6):1088-96. PubMed ID: 17360171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
    Meltzer SS; Hasday JD; Cohn J; Bleecker ER
    Am J Respir Crit Care Med; 1996 Mar; 153(3):931-5. PubMed ID: 8630575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).
    Calzetta L; Hanania NA; Dini FL; Goldstein MF; Fairweather WR; Howard WW; Cazzola M
    Pulm Pharmacol Ther; 2018 Dec; 53():20-26. PubMed ID: 30219705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma.
    Kubavat AH; Khippal N; Tak S; Rijhwani P; Bhargava S; Patel T; Shah N; Kshatriya RR; Mittal R
    Am J Ther; 2013; 20(2):154-62. PubMed ID: 22926233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β
    Wang Y; Chen P; Dai A; Shang S; Kong L
    Clin Ther; 2016 Dec; 38(12):2622-2627.e1. PubMed ID: 27913032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of enprofylline and theophylline in the maintenance therapy of chronic reversible obstructive airway disease.
    Chapman KR; Boucher S; Hyland RH; Day A; Kreisman H; Rivington R; Hodder RV; York EL; Abboud RT; Peters S
    J Allergy Clin Immunol; 1990 Feb; 85(2):514-21. PubMed ID: 2406328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
    van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
    Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.